About FoundationOne®

FoundationOne®  for solid tumour cancers

A validated, comprehensive genomic profiling assay

FoundationOne® interrogates the entire coding sequence of 315 cancer-related genes plus select introns from 28 genes often rearranged or altered in solid tumours. With the ability to detect all 4 classes of genomic alterations required to comprehensively profile a tumour, FoundationOne® can help reveal the alterations that are driving the growth of a patient's cancer and identify targeted treatment options that may not have been otherwise considered.

FoundationOne® can help you conserve tissue and save time, requiring only a small amount of tissue, including routine biopsy samples and FNA specimens, and allowing even low purity samples. Amplification of gene fragments via hybrid capture ensures adequate coverage of all unique fragments and maximises the chances of detection.

Benefits that go beyond the test itself

To help you discover actionable insights, results are provided through a user-friendly, interpretative report powered by a team of more than 20 bioinformaticians and genomic scientists. The report will identify all clinically relevant alterations and help match them to targeted therapies and clinical trials based on current scientific evidence and published clinical data. As a result, FoundationOne® may provide an expanded view of the options available to a given patient. 

see foundationone®  technical spec

About FoundationOne® Heme

FoundationOne® Heme for hematologic malignancies and sarcomas

A validated, comprehensive genomic profiling assay

FoundationOne® Heme interrogates the entire coding sequence of 405 cancer-related genes that are often rearranged or altered in hematologic malignancies (leukemias, lymphomas, and myeloma) and sarcomas. With the ability to detect all 4 classes of genomic alterations, FoundationOne® Heme can help reveal the alterations that are driving the growth of a patient's cancer and identify targeted treatment options that may not have been otherwise considered.

FoundationOne® Heme also employs RNA sequencing across 265 genes to capture a broad range of gene fusions, a type of alteration that is a common driver of hematologic cancers and sarcomas.

Benefits that go beyond the test itself

To help you discover actionable insights, results are provided through a user-friendly, interpretative report powered by a team of more than 20 bioinformaticians and genomic scientists. The report will identify all clinically relevant alterations and help match them to targeted therapies and clinical trials based on current scientific evidence and published clinical data. As a result, FoundationOne® Heme may provide an expanded view of the options for a given patient.

see foundationone® heme technical spec